Regor Therapeutics Strikes Deal with Genentech for CDK Inhibitors, Fetching USD 850 Million Upfront
Regor Therapeutics Group, a US-based biotech with significant ties to China, has entered into a...
China’s CDE Announces “Care Plan” to Include Pfizer’s Marstaximab for Rare Disease Drug Development
The National Health Commission (NHC) of China, through its Center for Drug Evaluation (CDE), has...
Genor Biopharma to Acquire EOC Pharma Group in a Merger Deal, Eyeing Commercialization Synergies
Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma...
WuXi AppTec and WuXi Biologics Weigh Asset Sales in US and Europe Over Biosecure Act Concerns
Reports emerged last week in the Financial Times suggesting that WuXi AppTec (HKG: 2359) and...
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in...
China’s National Healthcare Security Administration Issues Draft Guidelines for Long-Term Care Insurance
The National Healthcare Security Administration (NHSA) has released the “Draft Technical Guidelines for the Preparation...
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge...
China’s CDE Releases Draft Guidelines for Biosimilar Drug Labeling
On September 29, 2024, the Center for Drug Evaluation (CDE) of China’s National Medical Products...
Legend Biotech Corporation to Establish Advanced R&D Center in Philadelphia for Next-Generation Cell Therapies
Legend Biotech Corporation (NASDAQ: LEGN), a leading chimeric antigen receptor (CAR) T cell therapy specialist...
BeiGene Prices TEVIMBRA 10% Below Competitors Following FDA Approval for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the commercial availability of TEVIMBRA (Tislelizumab)...
Unixell Advances in Cell Therapy with CDE IND Acceptance
Shanghai-based Unixell Biotechnology Co., Ltd. has announced that its Investigational New Drug (IND) application for...
Duality Biotherapeutics’ BDCA2 ADC DB-2304 Phase I Trial Registered on ClinicalTrials.gov
Duality Biologics, Inc., a biopharmaceutical company specializing in the development of innovative therapies, has registered...
BeiGene’s FGFR2b ADC BG-C137 Enters Phase I Clinical Trial for Advanced Solid Tumors
On October 3, 2024, BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) registered a Phase I...
BMS Expands Opdivo Indication with FDA Approval for NSCLC Combo Therapy
The U.S. Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS,...
InnoCare Pharma’s Orelabrutinib Achieves Milestone in SLE Clinical Trial Enrollment
InnoCare Pharma announced on October 4, 2024, that it has completed patient enrollment in a...
Akeso Biopharma’s PD-1/VEGF Bispecific Antibody Study Completes Enrollment
On October 4, 2024, Summit Therapeutics (referred to as “Summit”), a partner of Akeso Biopharma...
FRα ADC Rina-S by Genmab Enters Late-Stage Clinical Trial Following ProfoundBio Acquisition
Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC...
Dizal Pharmaceutical’s Surufatinib Earns CDE Consideration for Breakthrough Therapy in EGFR exon20ins NSCLC
Dizal Pharmaceutical, a biopharmaceutical company based in China, has announced that the Center for Drug...
Hengrui Pharmaceuticals’ HR19042 Capsules Designated as Breakthrough Therapy for Autoimmune Hepatitis by China NMPA
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has recently...
NMPA Clears AbbVie’s ABBV-706 for Clinical Trials Targeting SCLC and Neuroendocrine Tumors
The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a...